All Updates

All Updates

icon
Filter
Partnerships
HAYA Therapeutics partners with Eli Lilly for preclinical drug discovery in obesity and metabolic conditions
Precision Medicine
Sep 4, 2024
This week:
Management news
6K Additive awarded project to develop C-103 powder for additive manufacturing
Additive Manufacturing
Sep 27, 2024
Partnerships
WAAM3D partners with Innovative Space Carrier, Cranfield University, and Aichi Sangyo for space transport development
Additive Manufacturing
Sep 19, 2024
Funding
INFINIT raises USD 6 million in funding to enhance infrastructure
Decentralized Finance (DeFi)
Yesterday
Product updates
Salesforce announces suite of AI-powered autonomous agent solutions
Workflow Automation Platforms
Yesterday
FDA approval
FDA approves Apple AirPods Pro as over-the-counter hearing aids
Age Tech
Yesterday
Partnerships
Paradigm Health and Sheba Medical partner to optimize clinical trials
Clinical Trial Technology
Yesterday
Funding
XP Health raises USD 33.2 million in Series B funding to expand vision care platform
Health Benefits Platforms
Yesterday
Product updates
Circle expands Web3 Services product suite to Arbitrum
Web3 Ecosystem
Yesterday
Management news
Exiger achieves FedRAMP Moderate Authorization for Federal Cloud
Supply Chain Tech
Yesterday
Product updates
Schouten Europe launches plant-based chicken schnitzel with new fiber technology
Plant-based Meat
Yesterday
Precision Medicine

Precision Medicine

Sep 4, 2024

HAYA Therapeutics partners with Eli Lilly for preclinical drug discovery in obesity and metabolic conditions

Partnerships

  • HAYA Therapeutics has inked a multi-year agreement with Eli Lilly for advancements in drug discovery treatments related to obesity and related metabolic diseases. As part of the agreement, HAYA will receive an upfront payment, including equity investment, and is eligible for up to USD 1 billion in preclinical, clinical, and commercial milestone payments, as well as royalties on product sales.

  • The agreement includes using HAYA's RNA-guided regulatory genome platform to support preclinical drug discovery, potentially leading to effective and less harmful treatments. 

  • Analyst QuickTake: The agreement between HAYA and Eli Lilly is a part of the latter’s recent plans to expand its scope and product pipeline. In June 2024, Eli Lilly entered an agreement with Radionetics Oncology to establish a path to potentially acquire the company and gain access to its pipeline of cancer radiotherapeutics. Additionally, in the same month, Eli Lilly acquired biopharmaceutical company Morphic Holding to expand its immunology portfolio and develop new therapies in gastroenterology.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.